In a male patient with chronic kidney disease (eGFR ~40 mL/min/1.73 m²) taking dapagliflozin who develops a sub‑preputial infection causing phimosis, how should the infection and phimosis be managed, and should dapagliflozin be continued?

Management of Sub-Preputial Infection with Phimosis in a CKD Patient on Dapagliflozin

Treat the infection aggressively with topical or systemic antifungal therapy (most likely candidal balanitis), temporarily discontinue dapagliflozin during the acute infection, and arrange urgent urology consultation for definitive management of the phimosis—either circumcision or preputioplasty—once the infection resolves.

Immediate Infection Management

The sub-preputial infection is almost certainly fungal (candidal balanitis), as this is the predominant genitourinary infection associated with SGLT2 inhibitors. Uncircumcised males are specifically identified as a risk factor for these infections 1. The infection should be treated with:

• Topical antifungal cream (clotrimazole or miconazole) applied twice daily for 7-14 days
• If severe or not responding: Oral fluconazole 150 mg as a single dose, repeatable in 3 days if needed
• Maintain meticulous hygiene with gentle retraction (if possible without forcing) and cleaning

Most genital infections with SGLT2 inhibitors are mild to moderate and respond to standard antimicrobial treatment 2. However, the development of phimotic stricture represents a complication requiring more aggressive intervention.

Dapagliflozin Management Decision

Temporarily discontinue dapagliflozin during the acute infection. Here's the reasoning:

The FDA label explicitly warns about genitourinary infections, particularly in uncircumcised males 1. While the drug provides significant renal protection in CKD (slowing eGFR decline, reducing cardiovascular death and heart failure hospitalization) 3, continuing it during an active infection that has already caused structural complications is contraindicated.

Key considerations for this patient with eGFR ~40:

• Dapagliflozin can be safely used at eGFR ≥25 mL/min/1.73 m² for cardiorenal protection 3
• The 2025 ADA guidelines strongly recommend SGLT2 inhibitors for CKD patients like this one, as dapagliflozin has proven benefits in slowing CKD progression 4
• However, the glucosuria mechanism (60-100g glucose/day excretion) 1 creates an ideal environment for ongoing infection

Definitive Surgical Management

Arrange urgent urology referral for circumcision or preputioplasty once infection clears. The phimosis represents a structural complication that will perpetuate infection risk and prevent adequate local hygiene. This is not optional—it's necessary to:

1. Eliminate the closed space where infection thrives
2. Allow proper hygiene and medication application
3. Enable safe resumption of dapagliflozin therapy

Phimosis with abnormal voiding or recurrent infections has documented associations with urinary tract complications 5, making surgical correction medically indicated rather than elective.

Resuming Dapagliflozin After Treatment

Resume dapagliflozin only after:

1. Complete resolution of infection (typically 2-4 weeks)
2. Definitive surgical correction of phimosis
3. Healing from circumcision/preputioplasty (usually 4-6 weeks post-procedure)

Once these conditions are met, restart dapagliflozin 10 mg daily given this patient's eGFR of 40 mL/min/1.73 m². The cardiorenal benefits are substantial—dapagliflozin reduces sustained eGFR decline, ESKD, cardiovascular death, and heart failure hospitalization in CKD patients 4, 3. Recent evidence shows it can even improve eGFR slope in patients with advanced CKD 6, 7.

Critical Pitfalls to Avoid

• Don't continue dapagliflozin through active infection with structural complications: The glucosuria will perpetuate the infection cycle
• Don't treat phimosis conservatively in this context: The structural problem must be corrected surgically to prevent recurrence
• Don't abandon dapagliflozin permanently: After surgical correction, the benefits for this CKD patient far outweigh risks, and post-circumcision infection rates drop dramatically
• Don't delay urology referral: The longer phimosis persists, the higher the risk of recurrent infection and further complications

Post-Circumcision Monitoring

After resuming dapagliflozin post-circumcision:

• Monitor for any signs of recurrent genital infection (should be rare after circumcision)
• Check renal function at 1-2 weeks (expect transient 3-5 mL/min eGFR dip that stabilizes) 1
• Continue monitoring eGFR every 3-6 months as clinically indicated 3
• Educate patient about genital hygiene and early infection signs

The combination of surgical correction plus dapagliflozin resumption provides optimal outcomes: eliminating the infection substrate while preserving critical cardiorenal protection in a CKD patient who stands to benefit substantially from SGLT2 inhibitor therapy 4, 8.